Oral Anticoagulation Therapy Use in Patients with Atrial Fibrillation After the Introduction of Non-vitamin K Antagonist Oral Anticoagulants: Findings from the French Healthcare Databases, 2011-2016

Overview

Journal BMJ Open

Specialty General Medicine

Date 2019 Apr 22

PMID 31005934

Citations 31

Authors

Geric Maura

Cecile Billionnet

Jerome Drouin

Alain Weill

Anke Neumann

Antoine Pariente

Affiliations

Soon will be listed here.

Abstract

Objectives: To describe (i) the trend in oral anticoagulant (OAC) use following the introduction of non-vitamin K antagonist oral anticoagulant (NOAC) therapy for stroke prevention in atrial fibrillation (AF) patients and (ii) the current patterns of use of NOAC therapy in new users with AF in France.

Design: (i) Repeated cross-sectional study and (ii) population-based cohort study.

Setting: French national healthcare databases (50 million beneficiaries).

Participants: (i) Patients with identified AF in 2011, 2013 and 2016 and (ii) patients with AF initiating OAC therapy in 2015-2016. PRIMARY AND SECONDARY OUTCOME MEASURES: (i) Trend in OAC therapy use in patients with AF and (ii) patterns of use of NOAC therapy in new users with AF.

Results: Between 2011 and 2016, use of OAC therapy moderately increased (+16%), while use of antiplatelet therapy decreased (-22%) among all patients with identified AF. In 2016, among the 1.1 million AF patients, 66% used OAC therapy and were more likely to be treated by vitamin K antagonist (VKA) than NOAC therapy, including patients at higher risk of stroke (63.5%), while 33% used antiplatelet therapy. Among 192 851 new users of OAC therapy in 2015-2016 with identified AF, NOAC therapy (66.3%) was initiated more frequently than VKA therapy, including in patients at higher risk of stroke (57.8%). Reduced doses were prescribed in 40% of NOAC new users. Several situations of inappropriate use at NOAC initiation were identified, including concomitant use of drugs increasing the risk of bleeding (one in three new users) and potential NOAC underdosing.

Conclusions: OAC therapy use in patients with AF remains suboptimal 4 years after the introduction of NOACs for stroke prevention in France and improvement in appropriate prescribing regarding NOAC initiation is needed. However, NOAC therapy is now the preferred drug class for initiation of OAC therapy in patients with AF, including in patients at higher risk of stroke.

Citing Articles

Prothrombin complex concentrate for reversal of oral anticoagulants in patients with oral anticoagulation-related critical bleeding: a systematic review of randomised clinical trials.

Ovesen C, Purrucker J, Grundtvig J, Mikkelsen T, Gluud C, Jakobsen J Scand J Trauma Resusc Emerg Med. 2025; 33(1):19.

PMID: 39905505 PMC: 11792222. DOI: 10.1186/s13049-025-01334-1.

Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.

Johnson L, Benz A, Shoamanesh A, Eikelboom J, Ezekowitz M, Giugliano R J Am Heart Assoc. 2024; 13(17):e034758.

PMID: 39190578 PMC: 11646504. DOI: 10.1161/JAHA.123.034758.

Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Comprehensive Review.

Perswani P, Yogarajah R, Saifuddin M, Lakhani A, Dasi J, Bhardwaj V Cureus. 2024; 16(7):e65347.

PMID: 39184779 PMC: 11344489. DOI: 10.7759/cureus.65347.

Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial.

Izumi C, Amano M, Fukushima S, Yaku H, Eishi K, Sakaguchi T Cardiovasc Drugs Ther. 2024; .

PMID: 38913220 DOI: 10.1007/s10557-024-07585-x.

Higher risk of traumatic intracranial hemorrhage with antiplatelet therapy compared to oral anticoagulation-a single-center experience.

Niklasson E, Svensson E, Andre L, Areskoug C, Forberg J, Vedin T Eur J Trauma Emerg Surg. 2024; 50(4):1237-1248.

PMID: 38512417 PMC: 11458661. DOI: 10.1007/s00068-024-02493-z.

References

Verheugt F, Granger C . Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet. 2015; 386(9990):303-10. DOI: 10.1016/S0140-6736(15)60245-8. View

Tuppin P, Rudant J, Constantinou P, Gastaldi-Menager C, Rachas A, de Roquefeuil L . Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017; 65 Suppl 4:S149-S167. DOI: 10.1016/j.respe.2017.05.004. View

Averlant L, Ficheur G, Ferret L, Boule S, Puisieux F, Luyckx M . Underuse of Oral Anticoagulants and Inappropriate Prescription of Antiplatelet Therapy in Older Inpatients with Atrial Fibrillation. Drugs Aging. 2017; 34(9):701-710. DOI: 10.1007/s40266-017-0477-3. View

Kjerpeseth L, Ellekjaer H, Selmer R, Ariansen I, Furu K, Skovlund E . Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol. 2017; 73(11):1417-1425. DOI: 10.1007/s00228-017-2296-1. View

Pisters R, van Vugt S, Brouwer M, Elvan A, Ten Holt W, Zwart P . Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Neth Heart J. 2017; 25(10):551-558. PMC: 5612862. DOI: 10.1007/s12471-017-1009-9. View

Steinberg B, Kim S, Thomas L, Fonarow G, Hylek E, Ansell J . Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation. 2014; 129(20):2005-12. PMC: 4050636. DOI: 10.1161/CIRCULATIONAHA.114.008643. View

Van de Werf F, Brueckmann M, Connolly S, Friedman J, Granger C, Hartter S . A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012; 163(6):931-937.e1. DOI: 10.1016/j.ahj.2012.03.011. View

Billionnet C, Alla F, Berigaud E, Pariente A, Maura G . Identifying atrial fibrillation in outpatients initiating oral anticoagulants based on medico-administrative data: results from the French national healthcare databases. Pharmacoepidemiol Drug Saf. 2017; 26(5):535-543. DOI: 10.1002/pds.4192. View

Olesen J, Sorensen R, Hansen M, Lamberts M, Weeke P, Mikkelsen A . Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace. 2014; 17(2):187-93. DOI: 10.1093/europace/euu225. View

10.

Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K . Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry. J Arrhythm. 2017; 33(4):289-296. PMC: 5529323. DOI: 10.1016/j.joa.2016.11.003. View

11.

Lafon T, Vallejo C, Hadj M, Laroche M, Geniaux H . [Misuse and adverse effects of new direct oral anticoagulants: A prospective observational study in patients admitted to an emergency unit of a French university hospital]. Therapie. 2017; 73(3):209-215. DOI: 10.1016/j.therap.2017.05.004. View

12.

Basaran O, Dogan V, Beton O, Tekinalp M, Aykan A, Kalaycioglu E . Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study. Medicine (Baltimore). 2016; 95(35):e4672. PMC: 5008576. DOI: 10.1097/MD.0000000000004672. View

13.

Ono T, Kohsaka S, Takatsuki S, Fukuda K, Suzuki M . Inconsistent Dosing of Non-Vitamin K Oral Anticoagulants: Differences Between the United States and Japan. J Am Coll Cardiol. 2017; 70(1):118. DOI: 10.1016/j.jacc.2017.03.609. View

14.

Broderick J, Bonomo J, Kissela B, Khoury J, Moomaw C, Alwell K . Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. Stroke. 2011; 42(9):2509-14. PMC: 3166233. DOI: 10.1161/STROKEAHA.110.611905. View

15.

Huiart L, Ferdynus C, Renoux C, Beaugrand A, Lafarge S, Bruneau L . Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. BMJ Open. 2018; 8(3):e018180. PMC: 5884337. DOI: 10.1136/bmjopen-2017-018180. View

16.

Rey G, Jougla E, Fouillet A, Hemon D . Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009; 9:33. PMC: 2637240. DOI: 10.1186/1471-2458-9-33. View

17.

Apenteng P, Gao H, Hobbs F, Fitzmaurice D . Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry. BMJ Open. 2018; 8(1):e018905. PMC: 5781154. DOI: 10.1136/bmjopen-2017-018905. View

18.

Bouillon K, Bertrand M, Boudali L, Ducimetiere P, Dray-Spira R, Zureik M . Short-Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care. J Am Heart Assoc. 2016; 5(11). PMC: 5210354. DOI: 10.1161/JAHA.116.004065. View

19.

Maura G, Blotiere P, Bouillon K, Billionnet C, Ricordeau P, Alla F . Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort.... Circulation. 2015; 132(13):1252-60. PMC: 4885525. DOI: 10.1161/CIRCULATIONAHA.115.015710. View

20.

Pisters R, Lane D, Nieuwlaat R, de Vos C, Crijns H, Lip G . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093-100. DOI: 10.1378/chest.10-0134. View